I-Mab appoints new CEO, shares fall

NovaBridge Biosciences

22/06/2023 18:23

** Shares of Chinese biotech company I-Mab  IMAB.O  fall as
much as 2.5% to $3.08
    ** Co appoints Raj Kannan as CEO, effective June 22
    ** Kannan most recently served as chief executive of Aerie
Pharmaceuticals
    ** IMAB says Andrew Zhu, who had served as acting CEO of
IMAB since Sept 2022, will continue as president and as a member
of the board
    ** Stock has fallen near 26% so far in 2023

 (Reporting by Anne Florentyna Gnanaraja Sekar in Bengaluru)
 ((AnneFlorentyna.GnanarajaSekar@thomsonreuters.com;))